^
Association details:
| Biomarker: | EGFR G719C + EGFR S768I |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | gefitinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Good Response to Gefitinib in Lung Adenocarcinoma of Complex Epidermal Growth Factor Receptor (EGFR ) Mutations with the Classical Mutation Pattern
Excerpt:
There were some common complex mutations among the 53 patients, such as three with V765M, L798H, K806E, and L814P; three with del‐19 and L861Q; two with del‐19 and L858R; two with L858R and R776H; two with L858R and S768I; two with L858R and G779S; and two with G719C and S768I (Table 4). Patients with all the above complex EGFR mutations had good responses (CR, PR, or SR) to EGFR TKIs.
DOI:
10.1634/theoncologist.2008-0093
